234 related articles for article (PubMed ID: 31429105)
1. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression.
Overbeek KA; Alblas M; Gausman V; Kandel P; Schweber AB; Brooks C; Van Riet PA; Wallace MB; Gonda TA; Cahen DL; Bruno MJ
Aliment Pharmacol Ther; 2019 Oct; 50(7):789-799. PubMed ID: 31429105
[TBL] [Abstract][Full Text] [Related]
2. International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression.
Overbeek KA; van Leeuwen N; Tacelli M; Anwar MS; Yousaf MN; Chhoda A; Arcidiacono PG; Gonda TA; Wallace MB; Capurso G; Farrell JJ; Cahen DL; Bruno MJ
United European Gastroenterol J; 2022 Mar; 10(2):169-178. PubMed ID: 35199484
[TBL] [Abstract][Full Text] [Related]
3. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort.
Gausman V; Kandel P; Van Riet PA; Moris M; Kayal M; Do C; Poneros JM; Sethi A; Gress FG; Schrope BA; Luk L; Hecht E; Jovani M; Bruno MJ; Cahen DL; Wallace MB; Gonda TA
Pancreas; 2018 Apr; 47(4):471-476. PubMed ID: 29521942
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Surveillance and Timeline of Progression of Presumed Low-Risk Intraductal Papillary Mucinous Neoplasms.
Kayal M; Luk L; Hecht EM; Do C; Schrope BA; Chabot JA; Gonda TA
AJR Am J Roentgenol; 2017 Aug; 209(2):320-326. PubMed ID: 28590817
[TBL] [Abstract][Full Text] [Related]
6. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Capurso G; Crippa S; Vanella G; Traini M; Zerboni G; Zaccari P; Belfiori G; Gentiluomo M; Pessarelli T; Petrone MC; Campa D; Falconi M; Arcidiacono PG
JAMA Netw Open; 2020 Nov; 3(11):e2022933. PubMed ID: 33252689
[TBL] [Abstract][Full Text] [Related]
8. Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features.
Kolb JM; Argiriadi P; Lee K; Liu X; Bagiella E; Gupta S; Lucas AL; Kim MK; Kumta NA; Nagula S; Sarpel U; DiMaio CJ
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1481-1487. PubMed ID: 29535058
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm.
Kashiwagi K; Minami K; Seino T; Hirata K; Iwasaki E; Inoue N; Iwao Y; Kanai T
J Dig Dis; 2019 Oct; 20(10):557-562. PubMed ID: 31322828
[TBL] [Abstract][Full Text] [Related]
10. Demographic features and natural history of intermediate-risk multifocal versus unifocal intraductal papillary mucinous neoplasms.
Rosenblatt R; Dorfman V; Epelboym I; Poneros JM; Sethi A; Lightdale C; Woo Y; Gress FG; Allendorf JD; Schrope BA; Chabot JA; Gonda TA
Pancreas; 2015 Apr; 44(3):478-83. PubMed ID: 25411806
[TBL] [Abstract][Full Text] [Related]
11. Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery.
Marchegiani G; Pollini T; Andrianello S; Tomasoni G; Biancotto M; Javed AA; Kinny-Köster B; Amini N; Han Y; Kim H; Kwon W; Kim M; Perri G; He J; Bassi C; Goh BK; Katz MH; Jang JY; Wolfgang C; Salvia R
JAMA Surg; 2021 Jul; 156(7):654-661. PubMed ID: 34009303
[TBL] [Abstract][Full Text] [Related]
12. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms.
Mukewar S; de Pretis N; Aryal-Khanal A; Ahmed N; Sah R; Enders F; Larson JJ; Levy MJ; Takahashi N; Topazian M; Pearson R; Vege SS; Chari ST
Gut; 2017 Oct; 66(10):1811-1817. PubMed ID: 27390303
[TBL] [Abstract][Full Text] [Related]
13. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata" of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness.
Kim M; Mi Jang K; Kim SH; Doo Song K; Jeong WK; Kang TW; Kim YK; Cha DI; Kim K; Yoo H
Acta Radiol; 2017 Oct; 58(10):1157-1166. PubMed ID: 28084815
[TBL] [Abstract][Full Text] [Related]
15. Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy.
Kwong WT; Lawson RD; Hunt G; Fehmi SM; Proudfoot JA; Xu R; Giap A; Tang RS; Gonzalez I; Krinsky ML; Savides TJ
Dig Dis Sci; 2015 Sep; 60(9):2800-6. PubMed ID: 25924899
[TBL] [Abstract][Full Text] [Related]
16. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
[TBL] [Abstract][Full Text] [Related]
17. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
[TBL] [Abstract][Full Text] [Related]
18. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
Mandai K; Uno K; Yasuda K
Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
[TBL] [Abstract][Full Text] [Related]
20. "High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas.
Aso T; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Ideno N; Osoegawa T; Takahata S; Shindo K; Ushijima Y; Aishima S; Oda Y; Ito T; Mizumoto K; Tanaka M
Pancreas; 2014 Nov; 43(8):1239-43. PubMed ID: 25036910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
